2017 DEA History Safety 
Cannabis Law Report
FEBRUARY 28, 2022
Patents on psychedelics raise unique concerns associated with their unusual qualities, history, and regulation. Controlled Substance Schedules , DRUG ENF’T ADMIN., [link] [ [link] ] (defining DEA criteria for categorization in Schedule I and listing psychedelic examples such as lysergic acid diethylamide (LSD), peyote, and MDMA).
Cannabis Law Report
JULY 9, 2021
Drug Enforcement Agency (“DEA”). Some physicians and therapists have argued that the Right to Try Act permits them to administer psilocybin to terminally ill patients (since studies are well past the Phase 1 stage), but the DEA has met this with resistance given psilocybin’s status as a Schedule I drug. AIMS Institute, PLLC.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JUNE 15, 2021
Prohibits the denial of employment or termination based upon a criminal history for drug possession. Charges HHS with establishing a “Commission on Substance Use, Health and Safety,” to determine the benchmark amounts for drug possession and publish an online report on their findings within 180 days.
Cannabis Law Report
MAY 1, 2019
For a business which has decided to publish ads for cannabis businesses, there are a number of steps that would minimize the risk of receiving a call from a federal prosecutor or a visit from your local DEA agent. See Medicinal and Adult-Use Cannabis Regulation and Safety Act, Cal. FOOTNOTES. & Prof. Code § 26032. 2 Ajax Letter.
Cannabis Law Report
APRIL 8, 2022
To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history. Later that year, Doblin sued the DEA for the first time. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer. Rick Doblin, Ph.D.,
Cannabis Law Report
JULY 1, 2021
In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency recognized psilocybin as a breakthrough therapy for treatment-resistant depression. Mason Marks: The project’s goal is to promote safety, innovation, equity, and accessibility in emerging psychedelics industries.
Cannabis Law Report
SEPTEMBER 23, 2019
Therefore, the AAFP advocates for further research into the overall safety and health effects of recreational use, as well as the effects of those laws on patient and societal health. The AAFP supports requirements testing current marijuana and cannabinoid products for safety, dosing, and product consistency. In the Exam Room.
Expert insights. Personalized for you.
52 
Let's personalize your content